BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

JHP Pharmaceuticals Announces Chief Executive Officer Succession


6/27/2011 5:58:53 AM

PARSIPPANY, N.J., June 24, 2011 /PRNewswire/ -- JHP Pharmaceuticals ("JHP") announced today that Stuart Hinchen would succeed Peter Jenkins as Chief Executive Officer of the company effective July 1, 2011. Stuart Hinchen has acted as JHP's President and Chief Operating Officer since the formation of the company in 2007.

Peter Jenkins commented: "Over the past four years we have established JHP on a secure financial and operational basis with growing revenues and strong profitability as well as put in place an assured platform for growth in both our marketed products and contract manufacturing business. In particular, over the past twelve months, we have established a rapidly growing pipeline of generic injectable products using both out-sourced development resources and an internal development group based at our Michigan manufacturing facility. The secure position the business is in provides me with the opportunity to step back from day to day activities knowing that the full time leadership of the business is in excellent hands. I will remain fully invested and also involved as a consultant with the business through supporting Stuart with the development activities."

Stuart Hinchen commented: "JHP has a wonderful opportunity over the coming years to actively redefine the generic injectable competitive landscape in the USA. Peter remains a valued architect of our business development efforts and how we progress the company through future growth."

About JHP Pharmaceuticals, LLC

JHP, headquartered in New Jersey, is a specialty pharmaceutical company which develops, manufactures and sells pharmaceutical products, primarily aseptic injectable products into the hospital segment, and provides contract manufacturing of sterile products for pharmaceutical companies. JHP is a private company wholly owned by JHP Holdings, LLC whose equity owners are Morgan Stanley Principal Investments, Peter Jenkins and Stuart Hinchen.

For more information, please visit www.jhppharma.com.

Contact:
Stuart Hinchen
973.658.3555
Peter Jenkins
973.658.3556

SOURCE JHP Pharmaceuticals



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES